<?xml version="1.0" encoding="utf-8"?><api:response xmlns:api="http://www.symplectic.co.uk/publications/api"><api:version uri="https://mypublications.shef.ac.uk/" elements-version="6.15.0.3976" schema-version="6.13" product-name="myPublications"/><api:request href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/961"/><api:result><api:object category="publication" id="961" last-affected-when="2024-03-14T05:57:23.23+00:00" last-modified-when="2024-03-14T05:57:23.23+00:00" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/961" created-when="2010-05-17T13:47:28.367+01:00" type-id="5" type-display-name="Journal article" type="journal-article"><api:privacy-level>Public</api:privacy-level><api:privacy-level-locked>false</api:privacy-level-locked><api:ever-approved>true</api:ever-approved><api:reporting-date-1>2000-04-01</api:reporting-date-1><api:allow-type-switching>true</api:allow-type-switching><api:records><api:record format="native" id="1918150" source-id="13" source-name="crossref" source-display-name="Crossref" id-at-source="10.1053/ctrv.1999.0163" last-modified-when="2022-09-11T15:19:48.3+01:00"><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="18786" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/18786"/></api:links><api:last-name>Hancock</api:last-name><api:initials>BW</api:initials><api:first-names>BW</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>W</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="967" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/967"/></api:links><api:last-name>Harris</api:last-name><api:initials>S</api:initials><api:first-names>S</api:first-names><api:separate-first-names><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Wheatley</api:last-name><api:initials>K</api:initials><api:first-names>K</api:first-names><api:separate-first-names><api:first-name>K</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Gore</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1053/ctrv.1999.0163</api:text><api:links><api:link type="doi" href="http://doi.org/10.1053/ctrv.1999.0163"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1053/ctrv.1999.0163"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0305-7372</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973701"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>2</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Cancer Treatment Reviews</api:text></api:field><api:field name="language" type="text" display-name="Language"><api:text>en</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>81</api:begin-page><api:end-page>89</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>4</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Elsevier BV</api:text></api:field><api:field name="publisher-url" type="text" display-name="Link 2"><api:text>http://dx.doi.org/10.1053/ctrv.1999.0163</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>16</api:day><api:month>5</api:month><api:year>2021</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Adjuvant interferon-alpha in malignant melanoma: current status</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>26</api:text></api:field></api:native></api:record><api:record format="native" id="961" source-id="2" source-name="pubmed" source-display-name="PubMed" id-at-source="10772966" last-modified-when="2020-04-28T21:27:05.483+01:00"><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>High-risk surgically resected primary or loco-regional cutaneous malignant melanoma, although uncommon, can be associated with less than 50% 5-year survival; adjuvant therapy of proven efficacy is therefore appropriate. Since immunological control mechanisms seem to be important in the natural history of melanoma, biological agents have been the subject of many adjuvant studies. Most popular has been recombinant interferon. Well over 4000 patients have been entered into randomized studies. Results suggest that there may be a clinical benefit, most clearly in relapse-free but also perhaps in overall survival. More precise estimates of the magnitude of any benefits are needed. The doses, schedules and cost-benefits have yet to be fully evaluated. Interferon cannot yet be recommended as standard adjuvant therapy in high-risk malignant melanoma.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="18786" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/18786"/></api:links><api:last-name>Hancock</api:last-name><api:initials>BW</api:initials><api:first-names>BW</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>W</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="full">Weston Park Hospital, Sheffield.</api:line></api:address></api:addresses></api:person><api:person><api:links><api:link type="elements/user" id="967" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/967"/></api:links><api:last-name>Harris</api:last-name><api:initials>S</api:initials><api:first-names>S</api:first-names><api:separate-first-names><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Wheatley</api:last-name><api:initials>K</api:initials><api:first-names>K</api:first-names><api:separate-first-names><api:first-name>K</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Gore</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.ncbi.nlm.nih.gov/pubmed/10772966</api:text></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1053/ctrv.1999.0163</api:text><api:links><api:link type="doi" href="http://doi.org/10.1053/ctrv.1999.0163"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1053/ctrv.1999.0163"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0305-7372</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973701"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>2</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Cancer Treat Rev</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Combined Modality Therapy</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Immunotherapy</api:keyword><api:keyword scheme="mesh">Interferon Type I</api:keyword><api:keyword scheme="mesh">Melanoma</api:keyword><api:keyword scheme="mesh">Randomized Controlled Trials as Topic</api:keyword><api:keyword scheme="mesh">Recombinant Proteins</api:keyword><api:keyword scheme="mesh">Skin Neoplasms</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="location" type="text" display-name="Country"><api:text>Netherlands</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>81</api:begin-page><api:end-page>89</api:end-page></api:pagination></api:field><api:field name="pii" type="text" display-name="PII"><api:text>S0305-7372(99)90163-9</api:text></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>4</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-made-public-at-source-date" type="date" display-name="Record made publicly available"><api:date><api:day>27</api:day><api:month>4</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Adjuvant interferon-alpha in malignant melanoma: current status.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item><api:item>Research Support, Non-U.S. Gov't</api:item><api:item>Review</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>26</api:text></api:field></api:native></api:record><api:record format="native" id="882160" source-id="18" source-name="epmc" source-display-name="Europe PubMed Central" id-at-source="MED:10772966" last-modified-when="2021-03-30T17:37:00.6+01:00"><api:citation-count>16</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>High-risk surgically resected primary or loco-regional cutaneous malignant melanoma, although uncommon, can be associated with less than 50% 5-year survival; adjuvant therapy of proven efficacy is therefore appropriate. Since immunological control mechanisms seem to be important in the natural history of melanoma, biological agents have been the subject of many adjuvant studies. Most popular has been recombinant interferon. Well over 4000 patients have been entered into randomized studies. Results suggest that there may be a clinical benefit, most clearly in relapse-free but also perhaps in overall survival. More precise estimates of the magnitude of any benefits are needed. The doses, schedules and cost-benefits have yet to be fully evaluated. Interferon cannot yet be recommended as standard adjuvant therapy in high-risk malignant melanoma.</api:text></api:field><api:field name="addresses" type="address-list" display-name="Addresses"><api:addresses><api:address iso-country-code="GB"><api:line type="full">Weston Park Hospital, Sheffield.</api:line></api:address></api:addresses></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="18786" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/18786"/></api:links><api:last-name>Hancock</api:last-name><api:initials>BW</api:initials><api:first-names>BW</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>W</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="967" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/967"/></api:links><api:last-name>Harris</api:last-name><api:initials>S</api:initials><api:first-names>S</api:first-names><api:separate-first-names><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Wheatley</api:last-name><api:initials>K</api:initials><api:first-names>K</api:first-names><api:separate-first-names><api:first-name>K</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Gore</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1053/ctrv.1999.0163</api:text><api:links><api:link type="doi" href="http://doi.org/10.1053/ctrv.1999.0163"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1053/ctrv.1999.0163"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1532-1967</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973701"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10772966</api:identifier></api:identifiers></api:field><api:field name="is-open-access" type="boolean" display-name="Open access"><api:boolean>false</api:boolean></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0305-7372</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973701"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>2</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Cancer treatment reviews</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Melanoma</api:keyword><api:keyword scheme="mesh">Skin Neoplasms</api:keyword><api:keyword scheme="mesh">Interferon Type I</api:keyword><api:keyword scheme="mesh">Recombinant Proteins</api:keyword><api:keyword scheme="mesh">Immunotherapy</api:keyword><api:keyword scheme="mesh">Combined Modality Therapy</api:keyword><api:keyword scheme="mesh">Randomized Controlled Trials as Topic</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="medium" type="text" display-name="Medium"><api:text>Print</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>81</api:begin-page><api:end-page>89</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>4</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>22</api:day><api:month>4</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Adjuvant interferon-alpha in malignant melanoma: current status.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Research Support, Non-U.S. Gov't</api:item><api:item>Review</api:item><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>26</api:text></api:field></api:native></api:record><api:record format="native" id="2931032" source-id="10" source-name="dimensions" source-display-name="Dimensions" id-at-source="pub.1009404641" last-modified-when="2024-02-04T10:09:36.847+00:00"><api:citation-count>20</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="18786" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/18786"/></api:links><api:last-name>Hancock</api:last-name><api:initials>BW</api:initials><api:first-names>BW</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>W</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01257257663.76</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="967" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/967"/></api:links><api:last-name>Harris</api:last-name><api:initials>S</api:initials><api:first-names>S</api:first-names><api:separate-first-names><api:first-name>S</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01272115415.97</api:identifier></api:identifiers></api:person><api:person><api:last-name>Wheatley</api:last-name><api:initials>K</api:initials><api:first-names>K</api:first-names><api:separate-first-names><api:first-name>K</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">University of Birmingham</api:line><api:line type="city">Birmingham</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01053706450.52</api:identifier></api:identifiers></api:person><api:person><api:last-name>Gore</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Royal Marsden Hospital</api:line><api:line type="city">London</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.011226554277.36</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1053/ctrv.1999.0163</api:text><api:links><api:link type="doi" href="http://doi.org/10.1053/ctrv.1999.0163"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1053/ctrv.1999.0163"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10772966</api:identifier></api:identifiers></api:field><api:field name="field-citation-ratio" type="decimal" display-name="Field citation ratio"><api:decimal>2.09</api:decimal></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0305-7372</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973701"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>2</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Cancer Treatment Reviews</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="for-2020">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020">3211 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="rcdc">Cancer</api:keyword><api:keyword scheme="rcdc">Patient Safety</api:keyword><api:keyword scheme="rcdc">Clinical Research</api:keyword><api:keyword scheme="hrcs-hc">Cancer</api:keyword><api:keyword scheme="mesh">Combined Modality Therapy</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Immunotherapy</api:keyword><api:keyword scheme="mesh">Interferon Type I</api:keyword><api:keyword scheme="mesh">Melanoma</api:keyword><api:keyword scheme="mesh">Randomized Controlled Trials as Topic</api:keyword><api:keyword scheme="mesh">Recombinant Proteins</api:keyword><api:keyword scheme="mesh">Skin Neoplasms</api:keyword></api:keywords></api:field><api:field name="open-access-status" type="text" display-name="Open access status"><api:text>Closed Access</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>81</api:begin-page><api:end-page>89</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>4</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Elsevier</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>31</api:day><api:month>8</api:month><api:year>2017</api:year></api:date></api:field><api:field name="relative-citation-ratio" type="decimal" display-name="Relative citation ratio"><api:decimal>0.48</api:decimal></api:field><api:field name="title" type="text" display-name="Title"><api:text>Adjuvant interferon-alpha in malignant melanoma: current status</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>26</api:text></api:field></api:native></api:record><api:record format="native" id="241464" source-id="11" source-name="wos-lite" source-display-name="Web of Science (Lite)" id-at-source="WOS:000086101400001" last-modified-when="2024-03-14T05:57:23.233+00:00"><api:citation-count>22</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="18786" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/18786"/></api:links><api:last-name>Hancock</api:last-name><api:initials>BW</api:initials><api:first-names>BW</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>W</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="967" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/967"/></api:links><api:last-name>Harris</api:last-name><api:initials>S</api:initials><api:first-names>S</api:first-names><api:separate-first-names><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Wheatley</api:last-name><api:initials>K</api:initials><api:first-names>K</api:first-names><api:separate-first-names><api:first-name>K</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Gore</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.webofscience.com/api/gateway?GWVersion=2&amp;SrcApp=sheffield_elements_live&amp;SrcAuth=WosAPI&amp;KeyUT=WOS:000086101400001&amp;DestLinkType=FullRecord&amp;DestApp=WOS_CPL</api:text></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1053/ctrv.1999.0163</api:text><api:links><api:link type="doi" href="http://doi.org/10.1053/ctrv.1999.0163"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1053/ctrv.1999.0163"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="isidoc">297UQ</api:identifier><api:identifier scheme="pubmed">10772966</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0305-7372</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973701"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>2</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>CANCER TREATMENT REVIEWS</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>interferon-alpha</api:keyword><api:keyword>adjuvant therapy</api:keyword><api:keyword>malignant melanoma</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>81</api:begin-page><api:end-page>89</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>Adjuvant interferon-alpha in malignant melanoma: current status</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Review</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>26</api:text></api:field></api:native></api:record><api:record format="native" id="24446" source-id="3" source-name="wos" source-display-name="Web of Science" id-at-source="WOS:000086101400001" last-modified-when="2014-07-25T11:06:43.86+01:00"><api:citation-count>19</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="18786" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/18786"/></api:links><api:last-name>Hancock</api:last-name><api:initials>BW</api:initials><api:first-names>BW</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>W</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="967" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/967"/></api:links><api:last-name>Harris</api:last-name><api:initials>S</api:initials><api:first-names>S</api:first-names><api:separate-first-names><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Wheatley</api:last-name><api:initials>K</api:initials><api:first-names>K</api:first-names><api:separate-first-names><api:first-name>K</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Gore</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0305-7372</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973701"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>2</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>CANCER TREAT REV</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>interferon-alpha</api:keyword><api:keyword>adjuvant therapy</api:keyword><api:keyword>malignant melanoma</api:keyword><api:keyword>LEUKOCYTE-A INTERFERON</api:keyword><api:keyword>RESECTED CUTANEOUS MELANOMA</api:keyword><api:keyword>COOPERATIVE-ONCOLOGY-GROUP</api:keyword><api:keyword>PHASE-II TRIAL</api:keyword><api:keyword>RANDOMIZED TRIAL</api:keyword><api:keyword>HIGH-RISK</api:keyword><api:keyword>CLINICAL-TRIAL</api:keyword><api:keyword>METASTATIC MELANOMA</api:keyword><api:keyword>IMPROVED SURVIVAL</api:keyword><api:keyword>IMMUNOTHERAPY</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>81</api:begin-page><api:end-page>89</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>4</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Adjuvant interferon-alpha in malignant melanoma: current status</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>26</api:text></api:field></api:native></api:record></api:records><api:fields/><api:all-labels type="keyword-list"><api:keywords><api:keyword scheme="mesh" origin="record-data" source="pubmed">Combined Modality Therapy</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Immunotherapy</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Interferon Type I</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Melanoma</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Randomized Controlled Trials as Topic</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Recombinant Proteins</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Skin Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Melanoma</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Skin Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Interferon Type I</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Recombinant Proteins</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Immunotherapy</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Combined Modality Therapy</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Randomized Controlled Trials as Topic</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3211 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Cancer</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Patient Safety</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Clinical Research</api:keyword><api:keyword scheme="hrcs-hc" origin="record-data" source="dimensions">Cancer</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Combined Modality Therapy</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Immunotherapy</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Interferon Type I</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Melanoma</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Randomized Controlled Trials as Topic</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Recombinant Proteins</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Skin Neoplasms</api:keyword><api:keyword origin="record-data" source="wos-lite">interferon-alpha</api:keyword><api:keyword origin="record-data" source="wos-lite">adjuvant therapy</api:keyword><api:keyword origin="record-data" source="wos-lite">malignant melanoma</api:keyword><api:keyword origin="record-data" source="wos">interferon-alpha</api:keyword><api:keyword origin="record-data" source="wos">adjuvant therapy</api:keyword><api:keyword origin="record-data" source="wos">malignant melanoma</api:keyword><api:keyword origin="record-data" source="wos">LEUKOCYTE-A INTERFERON</api:keyword><api:keyword origin="record-data" source="wos">RESECTED CUTANEOUS MELANOMA</api:keyword><api:keyword origin="record-data" source="wos">COOPERATIVE-ONCOLOGY-GROUP</api:keyword><api:keyword origin="record-data" source="wos">PHASE-II TRIAL</api:keyword><api:keyword origin="record-data" source="wos">RANDOMIZED TRIAL</api:keyword><api:keyword origin="record-data" source="wos">HIGH-RISK</api:keyword><api:keyword origin="record-data" source="wos">CLINICAL-TRIAL</api:keyword><api:keyword origin="record-data" source="wos">METASTATIC MELANOMA</api:keyword><api:keyword origin="record-data" source="wos">IMPROVED SURVIVAL</api:keyword><api:keyword origin="record-data" source="wos">IMMUNOTHERAPY</api:keyword><api:keyword scheme="for" origin="issn-inferred">1112 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="science-metrix" origin="issn-inferred">Oncology &amp; Carcinogenesis</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">3211 Oncology and carcinogenesis</api:keyword></api:keywords></api:all-labels><api:journal issn="0305-7372" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973701" title="Cancer Treatment Reviews"><api:records><api:record source-name="summary"><api:title>Cancer Treatment Reviews</api:title></api:record></api:records></api:journal><api:relationships href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/961/relationships"/></api:object></api:result></api:response>